Effects of 5-HT 2A and 5-HT 2C receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats

Behavioural Brain Research

Volumn 219, Issue 2, 2011, Pages 273-279

  Creed Carson, Meaghan ^a,b   Oraha, Alhan ^a,b   Nobrega, José N ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

5 HT 2 receptors; Catalepsy; Haloperidol; Ketanserin; M100,907; SB242,084; Tardive dyskinesia; Vacuous chewing movements

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; HALOPERIDOL; KETANSERIN; MESSENGER RNA; PROTEIN FOS; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; VOLINANSERIN;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CHRONIC DISEASE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG TARGETING; DYSKINESIA; FRONTAL CORTEX; MALE; MASTICATION; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMINOPYRIDINES; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CATALEPSY; DYSKINESIA, DRUG-INDUCED; FLUOROBENZENES; GENE EXPRESSION REGULATION; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INDOLES; KETANSERIN; MALE; MOUTH; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RNA, MESSENGER; SEROTONIN ANTAGONISTS;

EID: 79952702074     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.01.025     Document Type: Article

References (52)

1. Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007, 113:296-320.
2. Badiani A., Oates M.M., Fraioli S., Browman K.E., Ostrander M.M., Xue C.J., et al. Environmental modulation of the response to amphetamine: dissociation between changes in behavior and changes in dopamine and glutamate overflow in the rat striatal complex. Psychopharmacology (Berl) 2000, 151:166-174.
3. Buckland P.R., D'Souza U., Maher N.A., McGuffin P. The effects of antipsychotic drugs on the mRNA levels of serotonin 5HT2A and 5HT2C receptors. Brain Res Mol Brain Res 1997, 48:45-52.
4. Burnet P.W., Chen C.P., McGowan S., Franklin M., Harrison P.J. The effects of clozapine and haloperidol on serotonin-1A-2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 1996, 73:531-540.
5. Burnet P.W., Eastwood S.L. Harrison PJ 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996, 15:442-455.
6. Casey D.E. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004, 65Suppl9:25-28.
7. Chartoff E.H., Ward R.P., Dorsa D.M. Role of adenosine and N-methyl-d-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J Pharmacol Exp Ther 1999, 291:531-537.
8. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21:151-156.
9. De Deurwaerdere P., Navailles S., Berg K.A., Clarke W.P., Spampinato U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 2004, 24:3235-3241.
10. Di Giovanni G., De Deurwaerdere P., Di Mascio M., Di Matteo V., Esposito E., Spampinato U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 1999, 91:587-597.
11. Di Matteo V., Di Giovanni G., Di Mascio M., Esposito E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999, 38:1195-1205.
12. Eberle-Wang K., Lucki I., Chesselet M.F. A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 1996, 72:117-128.
13. Egan M.F., Ferguson J., Hyde T.M. Effects of rating parameters on assessment of neuroleptic-induced vacuous chewing movements. Pharmacol Biochem Behav 1996, 53:401-410.
14. Egan M.F., Hurd Y., Ferguson J., Bachus S.E., Hamid E.H., Hyde T.M. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl) 1996, 127:337-345.
15. Fletcher P.J., Grottick A.J., Higgins G.A. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 2002, 27:576-586.
16. Glazer W.M. Extrapyramidal side effects tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000, 61(Suppl. 3):16-21.
17. Huang X.F., Tan Y.Y., Huang X., Wang Q. Effect of chronic treatment with clozapine and haloperidol on 5-HT(2A and 2C) receptor mRNA expression in the rat brain. Neurosci Res 2007, 59:314-321.
18. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
19. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999, 156:286-293.
20. Kostrzewa R.M., Huang N.Y., Kostrzewa J.P., Nowak P., Brus R. Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox Res 2007, 11:41-50.
21. Ma J., Ye N., Cohen B.M. Expression of noradrenergic alpha1, serotoninergic 5HT2a and dopaminergic D2 receptors on neurons activated by typical and atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:647-657.
22. Marchese G., Bartholini F., Ruiu S., Casti P., Casu G.L., Pani L. Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. Eur J Pharmacol 2004, 483:65-69.
23. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L., et al. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to " early onset" vacuous chewing. Eur J Neurosci 2002, 15:1187-1196.
24. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1 D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989, 251:238-246.
25. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989, 25:390-392.
26. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991, 43:587-604.
27. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci U S A 1993, 90:3447-3451.
28. Naidu P.S., Kulkarni S.K. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol 2001, 428:81-86.
29. Natesan S., Reckless G.E., Barlow K.B., Nobrega J.N., Kapur S. Evaluation of N-desmethylclozapine as a potential antipsychotic-preclinical studies. Neuropsychopharmacology 2007, 32:1540-1549.
30. Natesan S., Reckless G.E., Barlow K.B., Odontiadis J., Nobrega J.N., Baker G.B., et al. The antipsychotic potential of l-stepholidine-a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology (Berl) 2008, 199:275-289.
31. Numan S., Lundgren K.H., Wright D.E., Herman J.P., Seroogy K.B. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res Mol Brain Res 1995, 29:391-396.
32. Paxinos G., Watson C The rat brain in stereotaxic coordinates 1998, Academic Press, New York.
33. Reavill C., Kettle A., Holland V., Riley G., Blackburn T.P. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 1999, 126:572-574.
34. Reavill C., Taylor S.G., Wood M.D., Ashmeade T., Austin N.E., Avenell K.Y., et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000, 294:1154-1165.
35. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed. Curr Opin Psychiatry 2007, 20:131-137.
36. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46:315-328.
37. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994, 271:1058-1066.
38. Sakharov D.A., Voronezhskaya E.E., Nezlin L., Baker M.W., Elekes K., Croll R.P. Tyrosine hydroxylase-negative, dopaminergic neurons are targets for transmitter-depleting action of haloperidol in the snail brain. Cell Mol Neurobiol 1996, 16:451-461.
39. Snijders R., Kramarcy N.R., Hurd R.W., Nemeroff C.B., Dunn A.J. Neurotensin induces catalepsy in mice. Neuropharmacology 1982, 21:465-468.
40. Soares K.V., McGrath J.J. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res 1999, 39:1-16. discussion 17-8.
41. Stahl S.M. Introduction: What makes an antipsychotic atypical. J Clin Psychiatry 1999, 60(Suppl. 10):3-4.
42. Takeuchi H., Ishigooka J., Kobayashi K., Watanabe S., Miura S. Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:679-691.
43. Tamminga C.A., Dale J.M., Goodman L., Kaneda H., Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl) 1990, 102:474-478.
44. Travis M.J., Busatto G.F., Pilowsky L.S., Kerwin R.W., Mulligan R., Gacinovic S., et al. 5-HT2A receptor occupancy in vivo and response to the new antipsychotics olanzapine and sertindole. Br J Psychiatry 1997, 171:290-291.
45. Turrone P., Remington G., Kapur S., Nobrega J.N. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology 2003, 28:1433-1439.
46. Turrone P., Remington G., Kapur S., Nobrega J.N. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 2003, 165:166-171.
47. Turrone P., Remington G., Nobrega J.N. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy. Neurosci Biobehav Rev 2002, 26:361-380.
48. Van Oekelen D., Luyten W.H., Leysen J.E. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 2003, 72:2429-2449.
49. Ward R.P., Dorsa D.M. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 1996, 370:405-414.
50. Wichmann T., DeLong M.R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol 2003, 91:9-18.
51. Wolf W.A., Bieganski G.J., Guillen V., Mignon L. Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced " early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology (Berl) 2005, 182:84-94.
52. Wu Q., Reith M.E., Walker Q.D., Kuhn C.M., Carroll F.I., Garris P.A. Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: an in vivo voltammetric study. J Neurosci 2002, 22:6272-6281.